Aktuellt
SENASTE
Redeye returns with an update following Genovis’ licensing deal with Selecta Biosciences – a deal that clearly validates the huge potential in the company and its SmartEnzymes. We have hiked our fair value range and argue that the stock is very attractive for the long-term investor thanks to significant optionality on the upside.
LÄS MER
